{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-017852","form_type":"8-K","ticker":"RARE","cik":"0001515673","company_name":"Ultragenyx Pharmaceutical Inc.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.191641+00:00","generated_at":"2026-06-15T21:44:09.037160+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ultragenyx Q1 revenue $100.5M (+26% YoY); net loss $164M; reaffirms FY 2023 guidance","bullets":["Crysvita revenue $76M (+28% YoY), Dojolvi $14.3M (+15%), Mepsevii $8.5M.","Net loss per share $2.33 vs $2.19 in Q1 2022; op ex $254.6M incl $31.9M stock comp.","Cash & equivalents $714.6M; reaffirms FY 2023 total revenue $425-450M, net cash used <$400M.","UX143 OI Phase 2 complete, data & Phase 3 initiation expected mid-2023.","GTX-102 expansion cohorts dosing; next data update in 2H 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-017852","json":"https://secwatch.observer/filing/0000950170-23-017852.json","markdown":"https://secwatch.observer/filing/0000950170-23-017852.md","text":"https://secwatch.observer/filing/0000950170-23-017852.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1515673/000095017023017852/0000950170-23-017852-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1515673/000095017023017852/rare-20230504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T21:44:09.037160+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b6f0524478a22dc30be633badc588d4d816f61dc","claim":"Ultragenyx Pharmaceutical Inc. reported First Quarter 2023 results: revenue $ 100,496, net income $ (163,972 ), EPS $ (2.33 ). Guidance reaffirmed.","evidence_excerpt":"Selected Financial Data (dollars in thousands, except per share amounts), (unaudited) Three Months Ended March 31, 2023 2022 Total revenues $ 100,496 $ 79,935 Operating expense: Cost of sales 12,257 6,100 Research and development 165,698 143,155 Selling, general and administrative 76,646 67,312 Total operating expense 254,601 216,567 Net loss $ (163,972 ) $ (152,320 ) Net loss per share, basic and diluted $ (2.33 ) $ (2.19 )","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017023017852/0000950170-23-017852-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"First Quarter 2023"},{"label":"Revenue","value":"$ 100,496"},{"label":"Net income","value":"$ (163,972 )"},{"label":"EPS","value":"$ (2.33 )"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}